Eplerenone 25 Mg Film Coated Tablets
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Eplerenone 25 mg Film-coated Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 25 mg of eplerenone.
Excipient with known effect
Each 25 mg film-coated tablet contains 38 mg of lactose monohydrate (equivalent to 36 mg of lactose anhydrous) (see section 4.4).
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Film-coated Tablet
Yellow, diamond-shaped, biconvex film-coated tablet, approximately 6.4 mm wide and 7.4 mm long, engraved with “E25” on one side and plain on the other.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Eplerenone is indicated:
• In addition to standard therapy including beta-blockers, to reduce the risk of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction (LVEF <40%) and clinical evidence of heart failure after recent myocardial infarction.
• In addition to standard optimal therapy, to reduce the risk of cardiovascular mortality and morbidity in adult patients with NYHA class II (chronic) heart failure and left ventricular systolic dysfunction (LVEF <30%) (see section 5.1).
4.2
Posology and method of administration
Posology
For the individual adjustment of dose, the strengths of 25 mg and 50 mg are available.
The maximum dose regimen is 50 mg daily.
For post-myocardial infarction heart failure patients:
The recommended maintenance dose of eplerenone is 50 mg once daily (OD). Treatment should be initiated at 25 mg once daily and titrated to the target dose of 50 mg once daily preferably within 4 weeks, taking into account the serum potassium level (see table 1). Eplerenone therapy should usually be started within 3-14 days after an acute myocardial infarction.
For patients with NYHA class II (chronic) heart failure:
For chronic heart failure NYHA class II patients, treatment should be initiated at a dose of 25 mg once daily and titrated to the target dose of 50 mg once daily preferably within 4 weeks; taking into account the serum potassium level (see Table 1 and section 4.4).
Patients with a serum potassium of >5.0 mmol/L should not be started on eplerenone (see section 4.3).
Serum potassium should be measured before initiating eplerenone therapy, within the first week and at one month after the start of treatment or dose adjustment. Serum potassium should be assessed as needed periodically thereafter.
After initiation, the dose should be adjusted based on the serum potassium level as shown in table 1.
Table 1: Dose adjustment table after initiation
|
Serum potassium (mmol/L) |
Action |
Dose adjustment |
|
<5.0 |
Increase |
25 mg EOD* to 25 mg OD* 25 mg OD* to 50 mg OD* |
|
5.0 - 5.4 |
Maintain |
No dose adjustment |
|
5.5 - 5.9 |
Decrease |
50 mg OD* to 25 mg OD* 25 mg OD* to 25 mg EOD* 25 mg EOD* to withhold |
|
>6.0 |
Withhold |
N/A |
* EOD: Every Other Day; OD: Once Daily
Following withholding eplerenone due to serum potassium >6.0 mmol/L, eplerenone can be re-started at a dose of 25 mg every other day when potassium levels have fallen below 5.0 mmol/L.
Paediatric _ population
The safety and efficacy of eplerenone in children and adolescents have not been established. Currently available data are described in section 5.1 and 5.2.
Older people
No initial dose adjustment is required in the elderly. Due to an age-related decline in renal function, the risk of hyperkalaemia is increased in elderly patients. This risk may be further increased when co-morbidity associated with increased systemic exposure is also present, in particular mild-to-moderate hepatic impairment. Periodic monitoring of serum potassium is recommended (see section 4.4).
No initial dose adjustment is required in patients with mild renal impairment. Periodic monitoring of serum potassium is recommended (see section 4.4) and doses adjusted according to Table 1.
Patients with moderate renal impairment (CrCl 30-60 ml/min) should be started at 25 mg every other day, and dose should be adjusted based on the potassium level (see Table 1). Periodic monitoring of serum potassium is recommended (see section 4.4).
There is no experience in patients with CrCl <50 ml/min with post MI heart failure. The use of eplerenone in these patients should be done cautiously.
Doses above 25 mg daily have not been studied in patients with CrCl <50 ml/min.
Patients with severe renal impairment (CrCl <30 ml/min) are contraindicated (see section 4.3).
Eplerenone is not dialysable.
Patients with hepatic impairment
No initial dosage adjustment is necessary for patients with mild-to-moderate hepatic impairment. Due to an increased systemic exposure to eplerenone in patients with mild-to-moderate hepatic impairment, frequent and regular monitoring of serum potassium is recommended in these patients, especially when elderly (see section 4.4).
Concomitant treatment
In case of concomitant treatment with mild to moderate CYP3A4 inhibitors, e.g. amiodarone, diltiazem and verapamil, a starting dose of 25 mg OD may be initiated. Dosing should not exceed 25 mg OD (see section 4.5).
Method of administration
Eplerenone Film-coated Tablets may be administered with or without food (see section 5.2). For oral use.
4.3 Contraindications
- Hypersensitivity to eplerenone or to any of the excipients listed in section 6.1
- Patients with serum potassium level >5.0 mmol/L at initiation
- Patients with severe renal insufficiency (eGFR <30 mL per minute per 1.73m2)
- Patients with severe hepatic insufficiency (Child-Pugh Class C)
- Patients receiving potassium-sparing diuretics, potassium-supplements or strong inhibitors of CYP3A4 (e.g. itraconazole, ketoconazole, ritonavir, nelfinavir, clarithromycin, telithromycin and nefazodone) (see section 4.5)
- The combination of an angiotensin converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB) with eplerenone
4.4 Special warnings and precautions for use
Hyperkalaemia:
Consistent with its mechanism of action, hyperkalaemia may occur with eplerenone. Serum potassium levels should be monitored in all patients at initiation of treatment and with a change in dosage. Thereafter, periodic monitoring is recommended especially in patients at risk for the development of hyperkalaemia, such as elderly patients, patients with renal insufficiency (see section 4.2) and patients with diabetes. The use of potassium supplements after initiation of eplerenone therapy is not recommended, due to an increased risk of hyperkalaemia. Dose reduction of eplerenone has been shown to decrease serum potassium levels. In one study, the addition of hydrochlorothiazide to eplerenone therapy has been shown to offset increases in serum potassium.
The risk of hyperkalaemia may increase when eplerenone is used in combination with an angiotensin converting enzyme (ACE) inhibitor and/or an angiotensin receptor blocker (ARB). The combination of an angiotensin converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB) with eplerenone should not be used (see sections 4.3 and 4.5).
Impaired renal function
Potassium levels should be monitored regularly in patients with impaired renal function, including diabetic microalbuminuria. The risk of hyperkalaemia increases with decreasing renal function. While the data from EPHESUS in patients with type 2 diabetes and microalbuminuria is limited, an increased occurrence of hyperkalaemia was observed in this small number of patients. Therefore, these patients should be treated with caution. Eplerenone is not removed by haemodialysis.
Impaired hepatic function
No elevations of serum potassium above 5.5 mmol/L were observed in patients with mild to moderate hepatic impairment (Child Pugh class A and B). Electrolyte levels should be monitored in patients with mild to moderate hepatic impairment. The use of eplerenone in patients with severe hepatic impairment has not been evaluated and its use is therefore contraindicated (see section 4.2 and 4.3).
CYP3A4 inducers
Coadministration of eplerenone with strong CYP3A4 inducers is not recommended (see section 4.5).
Lithium, ciclosporin, tacrolimus should be avoided during treatment with eplerenone (see section 4.5).
Lactose
The tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take it.
4.5 Interaction with other medicinal products and other forms of interaction
Potassium-sparing diuretics and potassium supplements:
Due to increased risk of hyperkalaemia, eplerenone should not be administered to patients receiving potassium-sparing diuretics and potassium supplements (see section 4.3). Potassium-sparing diuretics may potentiate the effect of antihypertensive agents and other diuretics.
ACE inhibitors, angiotensin receptor blockers (ARB): The risk of hyperkalaemia may increase when eplerenone is used in combination with an angiotensin converting enzyme (ACE) inhibitor and/or an angiotensin receptor blocker (ARB). A close monitoring of serum potassium and renal function is recommended, especially in patients at risk for impaired renal function, e.g., the elderly. The triple combination of an angiotensin converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB) with eplerenone should not be used (see sections 4.3 and 4.4).
Lithium: Interaction studies of eplerenone have not been conducted with lithium. However, lithium toxicity has been reported in patients receiving lithium concomitantly with diuretics and angiotensin-converting enzyme (ACE) inhibitors (see section 4.4). Coadministration of eplerenone and lithium should be avoided. If this combination appears necessary, lithium plasma concentrations should be monitored (see section 4.4).
Ciclosporin, tacrolimus: Ciclosporin and tacromilus may lead to impaired renal function and increase the risk of hyperkalaemia. The concomitant use of eplerenone and ciclosporin or tacrolimus should be avoided. If needed, close monitoring of serum potassium and renal function are recommended when ciclosporin and tacrolimus are to be administered during treatment with eplerenone (see section 4.4).
Non-steroidal anti-inflammatory drugs (NSAIDs): Treatment with NSAIDs may lead to acute renal failure by acting directly on glomerular filtration, especially in at-risk patients (elderly and/or dehydrated patients). Patients receiving eplerenone and NSAIDs should be adequately hydrated and be monitored for renal function prior to initiating treatment.
Trimethroprim: The concomitant administration of trimethroprim with eplerenone increases the risk of hyperkalaemia. Monitoring of serum potassium and renal function should be made, particularly in patients with renal impairment and in the elderly.
Alpha 1 blockers (e.g. prazosin, alfuzosin):When alpha-1-blockers are combined with eplerenone, there is the potential for increased hypotensive effect and/or postural hypotension. Clinical monitoring for postural hypotension is recommended during alpha-1-blocker coadministration.
Tricyclic anti-depressants, neuroleptics, amifostine, baclofen : Co-administration of these agents with eplerenone may potentially increase antihypertensive effects and risk of postural hypotension.
Glucocorticoids, tetracosactide
Co-administration of these agents with eplerenone may potentially decrease antihypertensive effects (sodium and fluid retention).
In vitro studies indicate that eplerenone is not an inhibitor of CYP1A2, CYP2C19, CYP2C9, CYP2D6 or CYP3A4 isozymes. Eplerenone is not a substrate or an inhibitor of P-Glycoprotein.
Digoxin: Systemic exposure (AUC) to digoxin increases by 16% (90% CI: 4%-30%) when co-administered with eplerenone Caution is warranted when digoxin is dosed near the upper limit of therapeutic range.
Warfarin: No clinically significant pharmacokinetic interactions have been observed with warfarin. Caution is warranted when warfarin is dosed near the upper limit of therapeutic range.
CYP3A4 substrates: Results of pharmacokinetic studies with CYP3A4 probe-substrates, i.e. midazolam and cisapride, showed no significant pharmacokinetic interactions when these agents were coadministered with eplerenone.
CYP3A4 inhibitors:
- Strong CYP3A4 inhibitors: Significant pharmacokinetic interactions may occur when eplerenone is coadministered with agents that inhibit the CYP3A4 enzyme. A strong inhibitor of CYP3A4 (ketoconazole 200 mg BID) led to a 441% increase in AUC of eplerenone (see section 4.3). The concomitant use of eplerenone with strong CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin, telithromycin and nefazadone, is contra-indicated (see section 4.3).
- Mild to moderate CYP3A4 inhibitors: Co-administration with erythromycin, saquinavir, amiodarone, diltiazem, verapamil, and fluconazole have led to significant pharmacokinetic interactions with rank order increases in AUC ranging from 98% to 187%. Eplerenone dosing should therefore not exceed 25 mg when mild to moderate inhibitors of CYP3A4 are coadministered with eplerenone (see sections 4.2).
CYP3A4 inducers: Co-administration of St John's Wort (a strong CYP3A4 inducer) with eplerenone caused a 30% decrease in eplerenone AUC. A more pronounced decrease in eplerenone AUC may occur with stronger CYP3A4 inducers such as rifampicin. Due to the risk of decreased eplerenone efficacy, the concomitant use of strong CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, phenobarbital, St John's Wort) with eplerenone is not recommended (see section 4.4).
Antacids: Based on the results of a pharmacokinetic clinical study, no significant interaction is expected when antacids are coadministered with eplerenone.
4.6 Fertility, pregnancy and lactation
Pregnancy:
There are no adequate data on the use of eplerenone in pregnant women. Animal studies did not indicate direct or indirect adverse effects with respect to pregnancy, embryofoetal development, parturition and postnatal development (see section 5.3). Caution should be exercised prescribing eplerenone to pregnant women.
Breast-feeding:
It is unknown if eplerenone is excreted in human breast milk after oral administration. However, preclinical data show that eplerenone and/or metabolites are present in rat breast
milk and that rat pups exposed by this route developed normally. Because of the unknown potential for adverse effects on the breast fed infant, a decision should be made whether to discontinue breast-feeding or discontinue eplerenone, taking into account the importance of the medicinal product to the mother.
Fertility:
There are no human data available on fertility.
4.7 Effects on ability to drive and use machines
No studies on the effect of eplerenone on the ability to drive or use machines have been performed. Eplerenone does not cause drowsiness or impairment of cognitive function but when driving vehicles or operating machines it should be taken into account that dizziness may occur during treatment.
4.8 Undesirable effects
In two studies (Eplerenone Post-acute Mycardial Infarction Heart Failure Efficacy and Survival Study [EPHESUS] and Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure [EMPHASIS-HF]), the overall incidence of adverse events reported with eplerenone was similar to placebo. The most frequent adverse event reported in the EMPHASIS-HF study was hyperkalaemia with an incidence rate of 8.7% and 4% for eplerenone and placebo respectively.
Adverse events reported below are those with suspected relationship to treatment and in excess of placebo or are serious and significantly in excess of placebo or have been observed during post marketing surveillance. Adverse events are listed by body system and absolute frequency. Frequencies are defined as common (>1/100 to <1/10); uncommon (>1/1000 to <1/100). Not known (cannot be estimated from the available data).
|
MedDRA system organ class |
Adverse reaction |
|
Infections and infestations Common Uncommon |
Infection pyelonephritis, pharyngitis |
|
Blood and lymphatic system disorders Uncommon |
eosinophilia |
|
Endocrine disorders Uncommon |
hypothyroidism |
|
Metabolism and nutrition disorders Common Uncommon |
hyperkalaemia (see section 4.3 and 4.4) hyponatraemia, dehydration, hypercholesterolaemia, hypertriglyceridaemia |
|
Psychiatric disorders Uncommon |
insomnia |
|
Nervous system disorders Common Uncommon |
dizziness, syncope headache, hypoaesthesia |
|
Cardiac disorders Common Uncommon |
myocardial infarction left ventricular failure, atrial fibrillation, tachycardia |
|
Vascular disorders Common Uncommon |
Hypotension arterial thrombosis limb, orthostatic hypotension |
|
Respiratory, thoracic and mediastinal disorders Common |
cough |
|
Gastrointestinal disorders Common Uncommon |
diarrhoea, nausea, constipation vomiting, flatulence |
|
Skin and subcutaneous tissue disorders Common Uncommon Not known |
rash, pruritus hyperhidrosis angioedema |
|
Musculoskeletal and connective tissue disorders Common Uncommon |
muscle spasms, musculoskeletal pain back pain |
|
Renal and urinary disorders Common |
renal impairment (see section 4.3 and 4.4) |
|
Hepatobiliary disorders Uncommon |
cholecystitis |
|
Reproductive system and breast disorders Uncommon |
gynaecomastia |
|
General disorders and administration site conditions Uncommon |
asthenia, malaise |
|
Investigations Common Uncommon |
Blood urea increased blood creatinine increased, epidermal growth factor receptor decreased, blood glucose increased |
In EPHESUS, there were numerically more cases of stroke in the elderly group (> 75 years old). There was however no statistical significant difference between the occurrence of stroke in the eplerenone (30) vs placebo (22) groups. In EMPHASIS-HF, the number of cases of stroke in the very elderly (> 75 years old) was 9 in the eplerenone group and 8 in the placebo group.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
4.9 Overdose
No cases of human overdose with eplerenone have been reported. The most likely manifestation of human overdose would be anticipated to be hypotension or hyperkalaemia. If symptomatic hypotension should occur, supportive treatment should be initiated. If hyperkalaemia develops, standard treatment should be initiated.
Eplerenone cannot be removed by haemodialysis. Eplerenone has been shown to bind extensively to charcoal.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: aldosterone antagonists ATC code: C03D A04
Mechanism of action
Eplerenone has relative selectivity in binding to recombinant human mineralocorticoid receptors compared to its binding to recombinant human glucocorticoid, progesterone and androgen receptors. Eplerenone prevents the binding of aldosterone, a key hormone in the renin-angiotensin-aldosterone system (RAAS), which is involved in the regulation of blood pressure and the pathophysiology of cardiovascular disease.
Pharmacodynamic effects
Eplerenone has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone.
In dose-ranging studies of chronic heart failure (NYHA classification II-IV), the addition of eplerenone to standard therapy resulted in expected dose-dependent increases in aldosterone. Similarly, in a cardiorenal substudy of EPHESUS, therapy with eplerenone led to a significant increase in aldosterone. These results confirm the blockade of the mineralocorticoid receptor in these populations.
Eplerenone was studied in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). EPHESUS was a double-blind, placebo-controlled study, of 3 year duration, in 6632 patients with acute myocardial infarction (MI), left ventricular dysfunction (as measured by left ventricular ejection fraction [LVEF] <40%), and clinical signs of heart failure. Within 3-14 days (median 7 days) after an acute MI, patients received eplerenone or placebo in addition to standard therapies at an initial dose 25 mg once daily and titrated to the target dose of 50 mg once daily after 4 weeks if serum potassium was <5.0 mmol/L. During the study patients received standard care including acetylsalicylic acid (92%), ACE inhibitors (90%), P-blockers (83%), nitrates (72%), loop diuretics (66%), or HMG-CoA reductase inhibitors (60%).
In EPHESUS, the co-primary endpoints were all-cause mortality and the combined endpoint of CV death or CV hospitalisation; 14.4 % of patients assigned to eplerenone and 16.7 % of patients assigned to placebo died (all causes), while 26.7 % of patients assigned to eplerenone and 30.0 % assigned to placebo met the combined endpoint of CV death or hospitalisation. Thus, in EPHESUS, eplerenone reduced the risk of death from any cause by 15% (RR 0.85; 95% CI, 0.75-0.96; p= 0.008) compared to placebo, primarily by reducing cardiovascular (CV) mortality. The risk of CV death or CV hospitalisation was reduced by 13% with eplerenone (RR 0.87; 95% CI, 0.79-0.95; p=0.002). The absolute risk reductions for the endpoints all cause mortality and CV mortality/hospitalisation were 2.3 and 3.3%, respectively. Clinical efficacy was primarily demonstrated when eplerenone therapy was initiated in patients aged <75 years old. The benefits of therapy in those patients over the age of 75 are unclear. NYHA functional classification improved or remained stable for a statistically significantly greater proportion of patients receiving eplerenone compared to placebo. The incidence of hyperkalaemia was 3.4 % in the eplerenone group vs 2.0 % in the placebo group (p <0.001). The incidence of hypokalaemia was 0.5 % in the eplerenone group vs 1.5 % in the placebo group (p <0.001).
No consistent effects of eplerenone on heart rate, QRS duration, or PR or QT interval were observed in 147 normal subjects evaluated for electrocardiographic changes during pharmacokinetic studies.
In the EMPHASIS-HF trial (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) the effect of eplerenone when added to standard therapy was investigated on clinical outcomes in patients with systolic heart failure and mild symptoms (NYHA functional class II).
Patients were included if they were at least 55 years old, had a left ventricular ejection fraction (LVEF) < 30% or LVEF < 35% in addition to QRS duration of > 130 msec, and were either hospitalized for cardiovascular (CV) reasons 6 months prior to inclusion or had a plasma level of B-type natriuretic peptide (BNP) of at least 250 pg/ml or a plasma level of N-terminal pro-BNP of at least 500 pg/ml in men (750 pg/ml in women). Eplerenone was started at a dose of 25 mg once daily and was increased after 4 weeks to 50 mg once daily if the serum potassium level was < 5.0 mmol/L. Alternatively, if the estimated GFR was 30-49 ml/min/1.73 m2, eplerenone was started at 25 mg on alternate days, and increased to 25 mg once daily.
In total, 2737 patients were randomized (double-blind) to the treatment with eplerenone or placebo including baseline therapy of diuretics (85%), ACE inhibitors (78%), angiotensin II receptor blockers (19%), beta blockers (87%), anti thrombotic drugs (88%), lipid lowering agents (63%), and digitalis glycosides (27%). The mean LVEF was ~26% and the mean QRS duration was ~122 msec. Most of the patients (83.4%) were previously hospitalized for CV reasons within 6 months of randomization, with around 50% of them due to heart failure. Around 20% of the patients had implantable defibrillators or cardiac resynchronization therapy.
The primary endpoint, death from cardiovascular causes or hospitalization for heart failure occurred in 249 patients (18.3%) in the eplerenone group and 356 patients (25.9%) in the placebo group (RR 0.63, 95% CI, 0.54-0.74; p<0.001). The effect of eplerenone on the primary endpoint outcomes was consistent across all pre-specified subgroups.
The secondary endpoint of all cause mortality was met by 171 patients (12.5%) in the eplerenone group and 213 patients (15.5%) in the placebo group (RR 0.76; 95% CI, 0.620.93; p = 0.008). Death from CV causes was reported in 147 (10.8%) patients in the eplerenone group and 185 (13.5%) patients in the placebo group (RR 0.76; 95% CI, 0.610.94; p = 0.01).
During the study, hyperkalaemia (serum potassium level > 5.5 mmol/L) was reported in 158 patients (11.8%) in the eplerenone group and 96 patients (7.2%) in the placebo group (p < 0.001). Hypokalaemia, defined as serum potassium levels < 4.0 mmol/L, was statistically lower with eplerenone when compared to placebo (38.9% for eplerenone compared to 48.4% for placebo, p<0.0001).
Paediatric population:
Eplerenone has not been studied in pediatric patients with heart failure.
In a 10 week study of paediatric patients with hypertension (age range 4 to 17 years, n=304), eplerenone, at doses (from 25 mg up to 100 mg per day) that produced exposure similar to that in adults, did not lower blood pressure effectively. In this study and in a 1-year paediatric safety study in 149 patients, the safety profile was similar to that of adults. Eplerenone has not been studied in hypertensive patients less than 4 years old because the study in older paediatric patients showed a lack of efficacy (See section 4.2).
Any (long term) effect on hormonal status in paediatric patients has not been studied.
5.2 Pharmacokinetic properties
Absorption
The absolute bioavailability of eplerenone is unknown. Maximum plasma concentrations are reached after about 2 hours. Both peak plasma levels (Cmax) and area under the curve (AUC) are dose proportional for doses of 10 to 100 mg and less than proportional at doses above 100 mg. Steady state is reached within 2 days. Absorption is not affected by food.
Distribution
The plasma protein binding of eplerenone is about 50% and is primarily bound to alpha 1-acid glycoproteins. The apparent volume of distribution at steady state is estimated at 50 (±7) L. Eplerenone does not preferentially bind to red blood cells.
Biotransformation
Eplerenone metabolism is primarily mediated via CYP3A4. No active metabolites of eplerenone have been identified in human plasma.
Elimination
Less than 5% of an eplerenone dose is recovered as unchanged substance in the urine and faeces. Following a single oral dose of radiolabeled medicinal product, approximately 32% of the dose was excreted in the faeces and approximately 67% was excreted in the urine. The elimination half-life of eplerenone is approximately 3 to 5 hours. The apparent plasma clearance is approximately 10 L/hr.
Special populations
Age, gender and race: The pharmacokinetics of eplerenone at a dose of 100 mg once daily have been investigated in the elderly (>65 years), in males and females, and in blacks. The pharmacokinetics of eplerenone did not differ significantly between males and females. At steady state, elderly subjects had increases in Cmax (22%) and AUC (45%) compared with younger subjects (18 to 45 years). At steady state, Cmax was 19% lower and AUC was 26% lower in blacks (see section 4.2).
Paediatric population : A population pharmacokinetic model for eplerenone concentrations from two studies in 51 paediatric hypertensive patients of ages 4-16 years identified that patient body weight had a statistically significant effect on eplerenone volume of distribution but not on its clearance. Eplerenone volume of distribution and peak exposure in a heavier paediatric patient are predicted to be similar to that in an adult of similar body weight; in a lighter 45 kg patient, the volume of distribution is about 40% lower and the peak exposure is predicted to be higher than typical adults. Eplerenone treatment was initiated at 25 mg once daily in paediatric patients and increased to 25 mg twice daily after 2 weeks and eventually to 50 mg twice daily, if clinically indicated. At these doses, the highest observed eplerenone concentrations in paediatric subjects were not substantially higher than those in adults initiated at 50 mg once daily.
Renal impairment:: The pharmacokinetics of eplerenone were evaluated in patients with varying degrees of renal insufficiency and in patients undergoing haemodialysis. Compared with control subjects, steady-state AUC and Cmax were increased by 38% and 24%, respectively, in patients with severe renal impairment and were decreased by 26% and 3%, respectively, in patients undergoing haemodialysis. No correlation was observed between plasma clearance of eplerenone and creatinine clearance. Eplerenone is not removed by haemodialysis (see section 4.4.).
Hepatic impairment: The pharmacokinetics of eplerenone 400 mg have been investigated in patients with moderate (Child-Pugh Class B) hepatic impairment and compared with normal subjects. Steady-state Cmax and AUC of eplerenone were increased by 3.6% and 42%, respectively (see section 4.2). Since the use of eplerenone has not been investigated in patients with severe hepatic impairment, eplerenone is contraindicated in this patients' group (see section 4.3).
Heart failure: The pharmacokinetics of eplerenone 50 mg were evaluated in patients with heart failure (NYHA classification II-IV). Compared with healthy subjects matched according to age, weight and gender, steady state AUC and Cmax in heart failure patients were 38% and 30% higher, respectively. Consistent with these results, a population pharmacokinetic analysis of eplerenone based on a subset of patients from EPHESUS indicates that clearance of eplerenone in patients with heart failure was similar to that in healthy elderly subjects.
5.3 Preclinical safety data
Preclinical studies on safety pharmacology, genotoxicity, carcinogenic potential and toxicity to reproduction revealed no special hazard for humans.
In repeated dose toxicity studies, prostate atrophy was observed in rats and dogs at exposure levels slightly above clinical exposure levels. The prostatic changes were not associated with adverse functional consequences. The clinical relevance of these findings is unknown.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Core
Lactose monohydrate Cellulose microcrystalline Crospovidone (type A)
Sodium laurilsulfate Talc (E553b)
Magnesium stearate
Film-coating:
Poly(vinyl alcohol) (E1203)
Titanium dioxide (E171)
Macrogol 3350 (E1521)
Talc (E553b)
Iron oxide, yellow (E172)
Iron oxide, red (E172)
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
2 years
6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.
6.5 Nature and contents of container
PVC/PVdC Aluminium blister: 1, 10, 20, 28, 30, 50, 56, 60, 90, 100 and 200 film-coated tablets
PVC/PVdC perforated, single dose aluminium blister: 20 x 1, 30 x 1, 50 x 1, 90 x 1, 100 x 1, 200 x 1 film-coated tablets. Calendar Pack: 30, 100 film-coated tablet.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
No special requirements.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7 MARKETING AUTHORISATION HOLDER
Teva UK Limited,
Brampton Road Hampden Park Eastbourne East Sussex BN22 9AG United Kingdom
8 MARKETING AUTHORISATION NUMBER(S)
PL 00289/1696
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
01/08/2014
10/10/2014